baber/WOPTO huggingface dataset:
Patent NZ-581324-A (NZ)
Title: Combination therapy with a compound acting as a platelet adp receptor inhibitor
Inventor: CONLEY PAMELA B
IPC: A61K31/517
Filed: 2008-05-02
Abstract: Disclosed herein is the use of a first therapeutic agent of [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2Hquinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of a condition in a mammal selected from the group consisting of acute myocardial infarction, stable angina, chronic stable angina, transient ischemic attacks, strokes, peripheral vascular disease, preeclampsia/eclampsia, deep venous thrombosis, embolism, disseminated intravascular coagulation and thrombotic cytopenic purpura, thrombotic and restenotic complications following invasive procedures resulting from angioplasty, carotid endarterectomy, post CABG (coronary arteryl bypass graft) surgery, vascular graft surgery, stent placements and insertion of endovascular devices and prosthesis, wherein the medicament is for administration in combination with a second therapeutic agent which is selected from the group consisting of betrixaban, a specific inhibitor of factor IXa, a specific inhibitor of factor XI, a specific inhibitor of factor XIa, a specific inhibitor of factor VIIa, YM-150, Daiichi DU-176b, N-{ (1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl} -1H-indole-6-carboxamede, apixaban, rivaroxaban, otamixaban, razaxaban, AZD0837, RB2006, ximelagatran, dabigatran, bivalirudin, argatroban, phenocoumarol, synthetic pentasaccharides, such as fondaparinux, idraparinux, biotinylated idraparinux; abciximab, eptifibatide, tirofiban, dipyridamole, Aggrenox, cilostazol, ifetroban, isogrel, furegrelate, resveratrol, ozagrel, an anticoagulant agent and an antiplatelet agent.
Patent NZ-584549-A (NZ)
Title: HOXA13 urine marker for detection of bladder cancer
Inventor: GUILFORD PARRY JOHN
IPC: C07H21/04
Filed: 2005-07-22
Abstract: Disclosed is the detection of bladder cancer through the analysis of urine to detect the buildup of urinary bladder tumor markers (UBTM) wherein the UBTM is comprised of homeo box A13 (HOXA13) and not significantly associated with blood.
Patent NZ-590334-A (NZ)
Title: ICOTINIB HYDROCHLORIDE (4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crownquinazoline hydrochloride), SYNTHESIS, CRYSTALLOGRAPHIC FORM, MEDICAL COMBINATION, AND USES THEREOF
Inventor: WANG YINXIANG
IPC: C07D491/056
Filed: 2009-07-07
Abstract: Disclosed is 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crownquinazoline hydrochloride, known as icotinib hydrochloride, and new crystalline forms thereof. Also disclosed are methods for preparing icotinib hydrochloride, the XRPD diffraction pattern of the new crystalline forms, pharmaceutical compositions containing the compound, use of the compound for the treatment of cancer and the intermediates of the compound.
Patent NZ-592206-A (NZ)
Title: Method of remediating livestock effluent using pool with differing levels having differing concentrations of dissolved oxygen
Inventor: TERRY MARK
IPC: C02F11/02
Filed: 2009-09-25
Abstract: A lagoon (102) of effluent is established, including a set of sub-portions at different levels in the lagoon associated with a corresponding set of concentrations of dissolved oxygen, each sub-portion of the lagoon having a different concentration of dissolved oxygen. An incubator (120) including a set of sub-portions associated with the set of concentrations of dissolved oxygen is established, each sub-portion of the incubator having a different concentration of dissolved oxygen. A volume of effluent from each sub-portion of the lagoon is transmitted to a corresponding sub-portion of an incubator having a substantially similar concentration of dissolved oxygen as the sub-portion of the lagoon. A first remediated volume of effluent is generated in the corresponding sub-portion of the incubator responsive to proliferating a first microorganism which uses a first compound in the volume of effluent as substrate for growth, the first microorganism enabling a first chemical reaction which alters the first compound.
Patent NZ-602866-A (NZ)
Title: False formwork for moulding concrete panels
Inventor: SLADOJEVIC ROBERT
IPC: B28B7/16
Filed: 2007-10-31
Abstract: A method of casting a concrete panel by erecting a plurality of sideforms on a base to define an outer periphery of a panel to be cast, erecting false formwork within the sideforms to define an opening in the panel to be cast, demarcating a portion of a periphery of the opening, mounting infill in the false formwork so that the infill lies at a level lower than a upper surface of the panel to be cast, pouring concrete into the sideforms so that the concrete overlies the infill to define a false skim coat over the opening; and allowing the concrete to set to provide an uninterrupted upper surface of the panel.
Patent NZ-603794-A (NZ)
Title: Syringe barrel adapter and needle assembly
Inventor: RAFFERTY CHRISTOPHER CHARLES
IPC: A61M5/32
Filed: 2011-05-04
Abstract: 603794 An adapter (300) mountable to a retractable syringe barrel (110) is disclosed. The adapter comprises a body that includes a needle portion and a barrel-engaging portion and a needle aperture. The adapter facilitates mounting a needle assembly (400) to the barrel. The needle assembly comprises a needle body and cannula and an immobile, compressible needle seal (430), wherein the needle body and the needle seal are releasably engaged. The needle seal is engageable with a needle portion of the adapter. The needle body comprises one or more fluid reclaim channels that facilitate efficient delivery of the fluid contents of the retractable syringe. The retractable syringe also comprises dual locking systems to impede or prevent re-use. A preferred object of the invention is to provide an adapter which obviates the need to have a particular barrel shape or configuration for mounting a needle assembly thereto.
Patent NZ-609359-A (NZ)
Title: Blood treatment apparatus with flow divider for limiting an electrical current
Inventor: HANSSON PER
IPC: A61M1/36
Filed: 2011-09-14
Abstract: A blood treatment apparatus (2) comprising a blood treatment unit (10), a blood line (20), and a fluid line (30). The blood line is configured to extract blood from a blood source (21), pass the blood through the blood treatment unit and deliver treated blood to a target vessel (22). The fluid line is configured pass treatment fluid through the blood treatment unit and deliver used treatment fluid to a fluid sink (32). A flow divider (40) is arranged in the fluid line and separates treatment fluid into to a first fluid section (51) and a second fluid section (53), thereby electrically isolating the fluid sections (51, 53) such that electrical current flowing in the fluid line between the fluid sections is limited. The flow divider is verified to electrically isolate the first fluid section from the second fluid section. The verification may comprise applying a voltage between the two fluid sections, across the flow divider, and measuring the resulting current, wherein a current below a threshold indicates electrical isolation. The flow divider may comprise a drip chamber, or a pump. The flow divider may be configured to create a gas gap or periodically open and close the fluid line, for generating the separation of treatment fluid in the fluid line.
Patent NZ-619868-A (NZ)
Title: Dairy based compositions with low lps
Inventor: DE VRIES YNTE PIET
IPC: A23L33/00
Filed: 2012-07-13
Abstract: A method to produce a dairy based food composition with low lipopolysaccharide (LPS) comprises the steps (a) Providing a milk with a storage time of less than 264 hours (11 days old), (b) Treating the milk such that at least 98wt% of the Gram negative bacteria is removed and (c) Heating the milk wherein at least 98wt% of the Gram negative bacteria is removed to 60-90 °C. The method can further comprises (d) Treating the milk with a micro filter of pore size of from 0.05-1.2 m such that at least a casein rich fraction and a serum protein rich fraction are obtained. The treatment to remove at least 98wt% of the bacteria is selected from the group consisting of Bacterial filtration with a poresize of 0.5-2.5 micron; Centrifugation; or Use of antibody to remove Gram negative bacteria. Dairy based food composition obtained by a method is further disclosed. Also disclosed is a dairy based food composition where the amount of lipopolysaccharide (LPS) is less than 4000E3 endotoxin units (EU) per liter ready to use food composition or where the amount of LPS is less than 30E3 endotoxin units (EU) per gram dry product.
Patent NZ-620485-A (NZ)
Title: Ror gamma modulators
Inventor: WOLFRUM CHRISTIAN
IPC: C07J71/00
Filed: 2012-09-18
Abstract: Provided is the use of polyhydroxylated cholane derivatives of formula II or IIa, wherein the variables are as defined in the specification, for the manufacture of a medicament for the treatment of type II diabetes and diseases, disorders and conditions which are related to type II diabetes, such as hyperglycemia. An example of the derivatives is 1beta,3alpha,7alpha,12alpha-Tetrahydroxy-5beta-cholan-24-oate.
Patent NZ-620664-A (NZ)
Title: Dispersing feedstocks and processing materials
Inventor: MASTERMAN THOMAS
IPC: C12M1/00
Filed: 2010-11-18
Abstract: A feedstock saccharification system which includes a tank, a delivery system to deliver a biomass feedstock and a liquid medium to the tank, a dispersing system to disperse the biomass feedstock in the liquid medium, a saccharifying agent delivery device to deliver a metered amount of a saccharifying agent to the tank and a mixer configured to mix the contents of the tank. The dispersing system is configured to draw the feedstock and liquid medium out of the tank and recirculate it back into the tank. The dispersing system has a chamber and, within the chamber, a rotating member which draws the feedstock and liquid medium into the chamber axially and expels a dispersion of the feedstock in the medium from the chamber radially.
Patent NZ-624650-A (NZ)
Title: Purification of anti-c-met antibodies
Inventor: PERSSON JOSEFINE
IPC: C07K16/28
Filed: 2012-11-20
Abstract: Disclosed is a method of purifying an anti-c-met antibody comprising keeping a composition comprising the anti-c-met antibody at a temperature of greater than 28°C and a pH between about pH 6 and about pH 8 for more than 6 hours, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.
Patent NZ-626574-A (NZ)
Title: Platelet lysate gel
Inventor: HOUZE THOMAS AVERELL
IPC: A61K35/19
Filed: 2012-11-23
Abstract: Disclosed is the use of a platelet lysate in the manufacture of a medicament for treating a wound, an anal fissure or vaginal atrophy in a patient in need thereof, wherein the platelet lysate is prepared by a method comprising subjecting a population of platelets to at least one freeze-thaw cycle, wherein the freeze portion of each cycle is carried out at a temperature lower than or equal to about -190°C. Also disclosed is a method of producing a pharmaceutical composition comprising platelet lysate comprising (a) subjecting a population of platelets to at least one freeze-thaw cycle, wherein the freeze portion of each cycle is carried out at a temperature lower than or equal to about -190 °C, and (b) mixing the platelet lysate with at least one pharmaceutically acceptable polymer and at least one pharmaceutically acceptable positively charged chemical species selected from the group consisting of lysine, arginine, histidine, aspartic acid, glutamic acid, alanine, methionine, proline, serine, asparagine, cysteine, polyamino acids, protamine, aminoguanidine, zinc ions and magnesium ions such that the resulting composition is an aqueous gel having a viscosity in the range of 1000 to 500,000 mPa•s (cps) at room temperature.
Patent NZ-629238-A (NZ)
Title: Enzyme preparations yielding a clean taste
Inventor: DE SWAAF MAXIMILIAAN PETER MARIE
IPC: C12N15/56
Filed: 2006-11-28
Abstract: Disclosed is a process to produce a dairy product which comprises adding a lactase preparation to a dairy product which comprises lactose and wherein said lactase is a neutral lactase which comprises less than 30 units arylsulfatase activity per NLU of lactase activity and wherein said lactase is expressed by an industrial production strain and wherein said industrial production strain is an Aspergillus, Trichoderma, Bacillus, Pseudomonas or Saccharomyces species or Picha pastoris, Hansenula polymorpha, Candida utilis or Yarrowia lipolytica.
Patent NZ-708563-A (NZ)
Title: Treatment of cancers using pi3 kinase isoform modulators
Inventor: STERN HOWARD
IPC: A61P35/00
Filed: 2013-11-01
Abstract: Disclosed herein is the are methods, kits, and pharmaceutical compositions that include compounds as selective inhibitors for PI3K gamma and delta. In particular, disclosed herein is the use of (S)-3-(1 -(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one (Compound 292) or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in the manufacture of a medicament formulated to treat a hematologic malignancy (optionally a relapsed or refractory hematologic malignancy). The medicament may be formulated for administration at from 25 mg twice daily to 75 mg twice daily per day of the compound or the pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. The medicament may also be formulated such that Compound 292 is used in conjunction with a BTK inhibitor or a BCL-2 inhibitor
Patent NZ-717029-A (NZ)
Title: System for the production of multi-strained yogurt
Inventor: ANASTASIADIS ACHILLEAS
IPC: B01D69/00
Filed: 2014-07-17
Abstract: The invention is directed to an arrangement for the production of a strained yoghurt on an industrial scale. The arrangement enables the natural straining by means of separation means with minimal stressing of the raw material, minimal loss of useful ingredients in the whey, and with the optimal stability of the characteristics of the final product. Yoghurt coagulum is pumped (via a pump 1) through a first stage strainer (A), and subsequently through a second stage strainer (B). Each straining stage comprises at least one filter that is made of a flexible straining membrane (6, 7, 8) which is spirally wound around a whey collection tube (9). Pressurised yoghurt enters the filter and its whey passes through the flexible straining membrane to a compartment (11) which leads the whey to the collection tube (9).
Patent NZ-717325-A (NZ)
Title: An interface including a foam cushioning element
Inventor: HOWARD SCOTT ALEXANDER
IPC: A62B18/08
Filed: 2009-03-04
Abstract: A respiratory mask assembly includes a frame (20) having a channel and a cushioning element (30) including a clip portion adapted for interference seal and retention in the channel. The cushioning element includes an interfacing portion constructed from foam and having a wider width than the clip portion.
Patent NZ-718868-A (NZ)
Title: Process for separating a synthetic turf product
Inventor: DENNIS ANDERSEN
IPC: B29B17/02
Filed: 2014-10-20
Abstract: The present invention relates to an improved method for reclaiming the individual components of synthetic or artificial turf product in a form almost similar to their original outset. The result is achieved by downsizing the synthetic turf product into a downsized turf material; separating the downsized turf material by sieving into at least a first fraction substantially comprising a mixture of backing material and additional components and a second fraction substantially comprising grass fiber components; separating the first fraction by specific gravity using air to provide a low density fraction substantially comprising backing material and a high density fraction substantially comprising additional components; separating the second fraction by specific gravity and size by providing an airflow directed upwards in a separator configured to cause a swirling motion whereby the lighter fraction is entrained upwards in the air flow and the heavy fraction is allowed to fall downwards; where the lighter fraction substantially comprises grass fiber components, and the heavy fraction substantially comprises a mixture of backing material and additional components; and collecting the low density fraction and the light fraction.
Patent NZ-727709-A (NZ)
Title: Pharmaceutical composition comprising 5alpha-reductase inhibitor
Inventor: KI MIN HYO
IPC: A61P17/14
Filed: 2015-07-20
Abstract: Disclosed is a composition comprising a 5α-reductase inhibitor. Forming a liquid crystal upon exposure to an aqueous fluid, the composition can release the 5α-reductase inhibitor at a constant rate over a long period of time. In addition, the composition can significantly alleviate irritations attributed to the topical administration of 5α-reductase inhibitors, and thus the composition has improved safety. The 5α-reductase inhibitors are used in the treatment of benign prostatic hyperplasia, androgenic alopecia and hypertrichosis, and as a therapeutic aid after radical prostatectomy.
Patent NZ-733251-A (NZ)
Title: Vehicle with a rotary control box and aerial work platform
Inventor: SHUGEN XU
IPC: G05D99/00
Filed: 2017-06-26
Abstract: A vehicle with an arm-type aerial platform comprising a vehicle frame, a driving system disposed on the vehicle frame, a control box and a locking device; the control box is disposed at a lateral side of the vehicle frame in a rotary manner; and the control box is electrically connected with the driving system; a casing is disposed at a lateral side of a base of the vehicle frame; a turning opening is defined at a lateral side of the casing for turning the control box into and out of the casing; and an edge of the control box is hinged to an upper edge of the turning opening; the control box is configured to be locked by the locking device at a predefined position, a plurality of buttons of the control box are configured to be accessible through an access opening when the control box is locked at the predefined position. This allows the control box to be more conveniently accessed by a user and provides for access to the corresponding controls when the control box is in a stowed position.
Patent NZ-745531-A (NZ)
Title: Methods for inhibiting angiogenesis in a subject in need thereof
Inventor: DUDLER THOMAS
IPC: C07K16/40
Filed: 2017-03-31
Abstract: In one aspect, the present invention provides methods for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from, or at risk for developing, an angiogenesis-dependent disease or condition, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis. In some embodiments of these aspects of the invention, the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof.
Patent NZ-761640-A (NZ)
Title: Method and apparatus for controlling a winemaking process
Inventor: DELLA TOFFOLA GIACOMO
IPC: C12G1/02
Filed: 2018-08-10
Abstract: A method for controlling a winemaking process wherein must is either obtained from a pressing step or is taken during pumping over from a maceration and fermentation tank, the method comprises the step of preselecting at least one colorimetric value of said must, colorimetrically measuring the must and comparing the colorimetric value measured with said preselected value. The preselecting step is performed with reference to a matrix of colors corresponding to given organoleptic qualities of the obtainable wine. In the case of a white or rose winemaking process, the deviation between the measured and preselected colorimetric value causes the must obtained from a pressing step to be sent to a second fermentation tank. In the case of a red winemaking process, the maceration and fermentation step is stopped and the must is transferred into an aging tank or barrel when the variation in the measured chromatic intensity ceases. Conventional winemaking processes tend to be require finer control. The invention aims to improve process efficiency by incorporating a color-matrix based automated controller.
Patent NZ-766631-A (NZ)
Title: Self-optimising respiratory therapy system
Inventor: BUCKLEY MARK DAVID
IPC: A62B18/02
Filed: 2015-07-31
Abstract: Methods or systems are implemented for treatment with or monitoring use of respiratory pressure therapy device(s). The device may be for a respiratory disorder. A processor, such as a processor of a server communicating with the therapy device, may analyse data relating to respiratory therapy delivered by the device. The processor may generate data in the processor representing a prediction, such as compliance prediction(s), about progress of therapy based on the analysis. The processor may compare a first prediction score concerning a current therapy session to a threshold. The processor may additionally compare the first success prediction score to a second success prediction score concerning a prior therapy session. The processor may trigger one or more communications concerning use of the respiratory therapy device based on these comparisons. An advantage of these communications is that they may be used to improve the chance of a patient becoming compliant with the treatment.
Patent NZ-770256-A (NZ)
Title: N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
Inventor: DAVIE REBECCA LOUISE
IPC: C07D401/06
Filed: 2015-11-26
Abstract: The present invention provides N-((het)arylmethyl)-heteroary-carboxyamide compounds of formula (I), compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein. The use of such compounds are particularly useful in therapy, such as in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated, for example retinal vascular permeability associated with diabetic retinopathy, diabetic macular edema, hereditary angioedema and the like.
Patent PT-101784-A (PT)
Title: Speed control system, for traffic on motorways and other conditioned access sites
IPC: G08G1/16
Filed: 1995-10-20
Abstract: The present invention relates to a speed control system on motorways, using a self-synchronizing clock system between the various input and output machines, which enables them to carry out real-time calculations for possible applications of a fine or other form of punishing the speeding infraction. The technical fields of this invention are: electronics and data processing, and it is intended to be used in speed control on motorways or other controlled access sites. <IMAGE>
Patent PT-103959-A (PT)
Title: Sistema controlador adaptador da velocidade de veículos a motor.
Inventor: LOPES JOAO BAPTISTA SILVA
IPC: B60K31/00
Filed: 2008-02-04
Abstract: O OBJECTO DO PRESENTE INVENTO RESPEITA A UM SISTEMA LIMITADOR E ADAPTADOR DA VELOCIDADE DE VEÍCULOS A MOTOR EM ESTRADAS COM LIMITAÇÃO DE VELOCIDADE, QUE UTILIZA SENSORES NO MOTOR QUE ENVIAM SINAIS A PONTOS COLOCADOS A DETERMINADOS INTERVALOS NESSA VIAS, OS QUAIS, POR SUA VEZ, ENVIAM SINAIS AO SISTEMA INJECTOR DE COMBUSTÍVEL DO VEÍCULO, DIMINUINDO, SE FOR CASO DISSO, O RESPECTIVO DÉBITO.